Vivus stock falls as company raises $202m in predicted offering: Chelsea next?
This article was originally published in Scrip
Executive Summary
A public offering of Vivus stock predicted on Monday by Scrip saw the company raise $202.5 million to help usher its obesity drug Qnexa towards its PDUFA date with the FDA in April. The underwritten offer of 8.5 million shares at $22.50 prompted a fall in Vivus' share price of 11%, a move also predicted by Scrip.